Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

751 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Association between Obesity and Efficacy of Psoriasis Therapies: An Expert Consensus Panel.
Burshtein J, Armstrong A, Chow M, DeBusk L, Glick B, Gottlieb AB, Gold LS, Korman NJ, Lio P, Merola J, Rosmarin D, Rosenberg A, Van Voorhees A, Lebwohl M. Burshtein J, et al. Among authors: lebwohl m. J Am Acad Dermatol. 2024 Dec 19:S0190-9622(24)03390-5. doi: 10.1016/j.jaad.2024.12.016. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 39709077
Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years.
Harris JE, Pandya AG, Lebwohl M, Hamzavi IH, Grimes P, Gottlieb AB, Sofen HL, Moore AY, Wang M, Kornacki D, Butler K, Rosmarin D. Harris JE, et al. Among authors: lebwohl m. Skin Health Dis. 2024 Aug 7;4(6):e404. doi: 10.1002/ski2.404. eCollection 2024 Dec. Skin Health Dis. 2024. PMID: 39624731 Free PMC article. No abstract available.
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials.
Armstrong AW, Lebwohl M, Warren RB, Sofen H, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp KA, Kisa RM, Vaile J, Berger V, Vritzali E, Hoyt K, Colombo MJ, Scotto J, Banerjee S, Strober B, Thaçi D, Blauvelt A. Armstrong AW, et al. Among authors: lebwohl m. JAMA Dermatol. 2024 Nov 27. doi: 10.1001/jamadermatol.2024.4688. Online ahead of print. JAMA Dermatol. 2024. PMID: 39602111
Brodalumab: Six-Year US Pharmacovigilance Report.
Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Yoon SH, Rawnsley NN, Goehring EL Jr, Mangin GD, Jacobson AA. Lebwohl MG, et al. Dermatol Ther (Heidelb). 2024 Nov 26. doi: 10.1007/s13555-024-01304-y. Online ahead of print. Dermatol Ther (Heidelb). 2024. PMID: 39589679
Criteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North America.
Strober B, Zhong Y, Sima A, Beeghly A, Eckmann T, Balagula E, Zhuo J, Lebwohl M. Strober B, et al. Among authors: lebwohl m. J Psoriasis Psoriatic Arthritis. 2024 Nov 21:24755303241302070. doi: 10.1177/24755303241302070. Online ahead of print. J Psoriasis Psoriatic Arthritis. 2024. PMID: 39583219 Free PMC article.
Case series of topical 1.5% ruxolitinib cream for pediatric vitiligo.
Meister HM, Lebwohl M, Silverberg N. Meister HM, et al. Among authors: lebwohl m. JAAD Case Rep. 2024 Apr 18;54:27-30. doi: 10.1016/j.jdcr.2024.02.034. eCollection 2024 Dec. JAAD Case Rep. 2024. PMID: 39583057 Free PMC article. No abstract available.
Psoriasis management tree based on comorbidity.
Amara S, Pasumarthi A, Parikh N, Kodali N, Lebwohl M, Monks G. Amara S, et al. Among authors: lebwohl m. Int J Dermatol. 2024 Oct 17. doi: 10.1111/ijd.17497. Online ahead of print. Int J Dermatol. 2024. PMID: 39420121 Review.
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis.
Augustin M, Gottlieb AB, Lebwohl M, Pinter A, Warren RB, Puig L, Warham R, Lambert J, Wiegratz S, Szilagyi B, Blauvelt A. Augustin M, et al. Among authors: lebwohl m. Dermatol Ther (Heidelb). 2024 Oct;14(10):2841-2857. doi: 10.1007/s13555-024-01261-6. Epub 2024 Sep 17. Dermatol Ther (Heidelb). 2024. PMID: 39285121 Free PMC article.
Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry.
Mease PJ, Blauvelt A, Sima AP, Beaty SW, Low R, Gomez B, Gurrola M, Lebwohl MG. Mease PJ, et al. Among authors: lebwohl mg. Dermatol Ther (Heidelb). 2024 Oct;14(10):2805-2825. doi: 10.1007/s13555-024-01258-1. Epub 2024 Sep 16. Dermatol Ther (Heidelb). 2024. PMID: 39283415 Free PMC article.
751 results